Acarbose EP Impurity A with high purity in stock CAS 1013621-79-8 CAS NO.1013621-79-8

Topbatt Chemical Co., Ltd., Established in 2019, located in Shenzhen, Guangdong Province, is a Manufacturer and Trading company which specialized in fine chemicals like Pharmaceutical Reference Standards and Stable Isotopes. Our Stable Isotopes product line including 2H Labelled APIs, Reagents and Intermediates, 13C Labelled Substance, 15N Labelled Substance and 18O Labelled Substance.

We own a number of Senior pharmaceutical synthetic engineer, analysis engineer and analytical testing instrument. It make us have more than 1700 varieties compouds with high purity in stock in a short time.

We can provide you not only stock items, but also Custom Synthesis Service.

All of our products provided with COA, HPLC/GC, HNMR, qNMR, MS Spectrum.

Contact us at 0086-18923794376 or email us at yehh@topbatt.net, 24/7 stand by for you.

After-sales issues will be settled in 24 hours.

Product Name: Acarbose EP Impurity A

Chemical Name: (2S,3S,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-2,3,5-triol

Molecular Formula: C25H43NO18

Molecular Weight: 645.61

CAS#: 1013621-79-8(open form)

Purity: >95%

Appearence: White to Pale Yellow Solid

Price: Negotiable

Available Document: COA, HPLC/GC, HNMR, qNMR, MS Spectrum

Payment Term: Payment in advance by T/T.

Shipment: Package will dispatched in 7-15 days(According to the date of payment) by air.

Trade Term: EXW, FOB, CFR, DDU, DDP, ect.

Acarbose EP Impurity A is an impurity of Acarbose. Acarbose is an inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)